[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338099-105":59,"doc-detail-338099-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cardiovascular-risk-in-philadelphia-negative-myeloproliferative-neoplasms-a-narrative-review-key-mechanisms-and-implications","Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms - A Narrative Review - Key Mechanisms and Implications","","Myeloproliferative neoplasms (MPNs) include polycythemia vera, essential thrombocythemia, and primary myelofibrosis, all defined by clonal hematopoiesis without the Philadelphia chromosome. The JAK2 V617F mutation is common across MPN subtypes, while MPL and CALR alterations contribute in additional subsets, including triple-negative cases. MPNs increase thrombotic tendency and cardiovascular morbidity through chronic inflammation from abnormal leukocytes and platelets, driving atherosclerosis and vascular remodeling. Complications such as pulmonary hypertension and cardiac fibrosis further reduce survival, particularly in PMF.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cardiovascular-risk-in-philadelphia-negative-myeloproliferative-neoplasms-a-narrative-review-key-mechanisms-and-implications/338099/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cardiovascular-risk-in-philadelphia-negative-myeloproliferative-neoplasms-a-narrative-review-key-mechanisms-and-implications/338099.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What makes myeloproliferative neoplasms Philadelphia-negative, and which disorders are included?","Question",{"text":112,"@type":113},"MPNs involve clonal hematopoiesis without the Philadelphia chromosome. The review focuses on polycythemia vera, essential thrombocythemia, and primary myelofibrosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which genetic mutations are most relevant for cardiovascular risk in MPNs?",{"text":117,"@type":113},"JAK2 V617F is prevalent across PV, ET, and PMF. MPL and CALR mutations also play key roles, and some patients are triple-negative, involving other regulatory alterations.",{"name":119,"@type":110,"acceptedAnswer":120},"How do chronic inflammation and vascular changes contribute to cardiovascular outcomes in MPN patients?",{"text":121,"@type":113},"Inflammation driven by cytokine release from aberrant leukocytes and platelets increases cardiovascular risk. It promotes mechanisms such as atherosclerosis and vascular remodeling, and complications like pulmonary hypertension and cardiac fibrosis add to morbidity and mortality.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338099,1790154406,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Review  \nCardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications—A Narrative Review  \nSamuel Bogdan Todor†, Cristian Ichim *,‡, Adrian Boicean *,‡ and Romeo Gabriel Mihaila †  \nCitation: Todor, S.B.; Ichim, C.; Boicean, A.; Mihaila, R.G. Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms:  \nMechanisms and Implications—A Narrative Review. Curr. Issues Mol. Biol. 2024, 46, 8407–8423. [https://](https://)[ ](https://)[doi.org/10.3390/cimb46080496](doi.org/10.3390/cimb46080496)  \nAcademic Editor: Myunggon Ko  \nReceived: 8 July 2024  \nRevised: 24 July 2024  \nAccepted: 31 July 2024  \nPublished: 2 August 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nFaculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania; [samuelbogdant@gmail.com](samuelbogdant@gmail.com) (S.B.T.); romeo.mihaila@ulbsibiu.ro (R.G.M.)  \n* Correspondence: [cristian.ichim@ulbsibiu.ro](cristian.ichim@ulbsibiu.ro) (C.I.); [adrian.boicean@ulbsibiu.ro](adrian.boicean@ulbsibiu.ro) (A.B.)† These authors contributed equally to this work.  \n‡ These authors have/share the same contribution as corresponding author.  \nAbstract: Myeloproliferative neoplasms (MPNs), encompassing disorders like polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are characterized by clonal hematopoiesis without the Philadelphia chromosome. The JAK2 V617F mutation is prevalent in PV, ET, and PMF, while mutations in MPL and CALR also play significant roles. These conditions predispose patients to thrombotic events, with PMF exhibiting the lowest survival among MPNs. Chronic inflammation, driven by cytokine release from aberrant leukocytes and platelets, amplifies cardiovascular risk through various mechanisms, including atherosclerosis and vascular remodeling. Additionally, MPN-related complications like pulmonary hypertension and cardiac fibrosis contribute to cardiovascular morbidity and mortality. This review consolidates recent research on MPNs’ cardiovascular implications, emphasizing thrombotic risk, chronic inflammation, and vascular stiffness. Understanding these associations is crucial for developing targeted therapies and improving outcomes in MPN patients.  \nKeywords: myeloproliferative neoplasms; cytokines dysregulations; JAK 2 mutation; essential thrombocythemia; polycythemia vera; primary myelofibrosis  \n1. Introduction  \nMyeloproliferative neoplasms (MPNs) are malignant hematologic diseases characterized by the clonal production of hematopoietic cells. These disorders encompass polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) [1] . They share a common characteristic in that they lack the Philadelphia chromosome [2] . The overall age-standardized incidence of MPNs was found to be 4.45 cases per 100,000 personyears for all MPNs combined. Specifically, the incidence rates were 1.48 for PV, 1.60 for ET, and 0.53 for PMF, with higher rates among older age groups [3] . The occurrence of the JAK2 V617F (Janus Kinase 2) mutation is notably high, up to 97% in individuals with PV and approximately 60% in those with ET and PMF, with no significant difference between prefibrotic and overt PMF [4–7] . Furthermore, anomalies in the thrombopoietin receptor MPL are observed in 5% of patients with ET and PMF but are absent in patients with PV [8,9] . For the majority of ET and PMF patients without mutations in JAK2 or MPL, Calreticulin (CALR) variants are prevalent, occurring in 25% of cases [10,11] . However, some patients are classified as triple-negative MPN, meaning they lack any of the genetic anomalies. In these cases, e","cbCailfdh3Z90pQ9","https://ap.wps.com/l/cbCailfdh3Z90pQ9","pdf",1399768,17,"English","# Introduction\n## Philadelphia-negative MPNs and incidence\n## Genetic drivers: JAK2, MPL, CALR, and triple-negative disease\n## Thrombotic burden and survival across MPN subtypes\n## Cardiovascular complications: inflammation, vascular remodeling, and organ outcomes","[{\"question\":\"What makes myeloproliferative neoplasms Philadelphia-negative, and which disorders are included?\",\"answer\":\"MPNs involve clonal hematopoiesis without the Philadelphia chromosome. The review focuses on polycythemia vera, essential thrombocythemia, and primary myelofibrosis.\"},{\"question\":\"Which genetic mutations are most relevant for cardiovascular risk in MPNs?\",\"answer\":\"JAK2 V617F is prevalent across PV, ET, and PMF. MPL and CALR mutations also play key roles, and some patients are triple-negative, involving other regulatory alterations.\"},{\"question\":\"How do chronic inflammation and vascular changes contribute to cardiovascular outcomes in MPN patients?\",\"answer\":\"Inflammation driven by cytokine release from aberrant leukocytes and platelets increases cardiovascular risk. It promotes mechanisms such as atherosclerosis and vascular remodeling, and complications like pulmonary hypertension and cardiac fibrosis add to morbidity and mortality.\"}]","Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms - A Narrative Review - Key Mechanisms and Implications | PDF",1790021951,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a192bfc8a3ec6715ebb7919a75fa99f0.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20588fbe46d3694eba9282b0694c91c1.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6abaea36c40b0fef978efb49d6f389a.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4cb104ab9a525485fc857c56f77a84fa.webp",980,1385]